Last updated: July 31, 2026
Propoxyphene napsylate has no viable U.S. commercial market and no active development pathway. The drug was withdrawn from the United States in 2010 after FDA review linked propoxyphene exposure to potentially fatal cardiac rhythm abnormalities. Current clinical-trial activity, branded sales, generic competition, licensing activity and patent-based launch barriers are effectively absent. A conventional market-growth forecast is therefore not meaningful; the addressable approved-product market is projected to remain approximately zero in the United States.
What is the current FDA status of propoxyphene napsylate?
Propoxyphene napsylate is a salt form of propoxyphene, an opioid analgesic formerly marketed in the United States under products including Darvon-N. FDA requested withdrawal of all propoxyphene products from the U.S. market in November 2010 after new evidence showed that therapeutic dosing could produce changes in cardiac electrical activity, including QT prolongation, QRS widening and PR-interval prolongation.[1]
| Regulatory item |
Status |
| Active FDA approval |
No current U.S. commercial approval |
| U.S. market status |
Withdrawn in 2010 |
| Primary reason for withdrawal |
Cardiac toxicity and risk of potentially fatal arrhythmias |
| Drug class |
Opioid analgesic |
| Propoxyphene napsylate status |
Discontinued |
| Current FDA development pathway |
No meaningful active pathway |
| Controlled-substance history |
Previously controlled as a Schedule IV substance in the United States |
FDA stated that the risks could not be adequately managed through labeling changes or restricted prescribing. The agency advised patients to stop using propoxyphene and transition to alternative pain medicines through their prescribers.[1]
Are there active clinical trials for propoxyphene napsylate?
No active clinical-development program for propoxyphene napsylate is commercially evident. The drug is not a current candidate for analgesic development, reformulation, or label expansion.
Historical clinical work focused on analgesic efficacy, combination products and post-marketing safety. The 2010 regulatory action ended the commercial rationale for new interventional trials in the United States. Any future trial would face a high safety and regulatory burden because the cardiac risk is associated with the active drug rather than a narrow manufacturing defect.
Clinical-trial outlook
| Development category |
Current outlook |
| Phase 1 pharmacology studies |
No commercial rationale |
| Phase 2 analgesic studies |
No active development basis |
| Phase 3 registration trials |
Not expected |
| Pediatric studies |
No active pathway |
| New formulation studies |
Commercially unattractive |
| Combination-product studies |
Unlikely |
| Post-marketing safety studies |
Historical rather than developmental |
| Repurposing studies |
No established program |
A new sponsor would need to overcome the known electrophysiologic risk, demonstrate a clinically meaningful benefit over safer analgesics and obtain regulatory acceptance for renewed exposure to a withdrawn opioid. That profile makes a conventional return to market improbable.
When did propoxyphene napsylate lose exclusivity?
Propoxyphene napsylate has no commercially relevant remaining exclusivity. The original product and formulation patents date from the earlier opioid-analgesic market and would have expired before the 2010 withdrawal. The practical barrier to entry is therefore not patent protection. It is the absence of an approved commercial market and the safety rationale underlying withdrawal.
The relevant exclusivity categories are:
| Exclusivity type |
Current status |
| Composition-of-matter patent |
Expired |
| Basic formulation patents |
Expired or commercially irrelevant |
| FDA new-drug exclusivity |
Expired |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
Not commercially relevant |
| Regulatory data exclusivity |
Expired |
| Active Orange Book patent barrier |
No current commercial significance |
Exact historical patent numbers are not necessary to explain current market access. Even a technically unexpired secondary patent would not restore the product’s commercial value without an FDA-approved product and a viable safety profile.
What is the Orange Book status of propoxyphene napsylate?
Propoxyphene products may appear in historical FDA product records or discontinued-product databases, but they do not represent an active Orange Book protection strategy. The FDA Orange Book distinguishes discontinued products from products with active marketing status. A discontinued listing does not create a current commercial opportunity or an enforceable exclusivity position.
No active Paragraph IV litigation landscape is associated with propoxyphene napsylate. The product’s withdrawal eliminated the principal commercial incentive for generic applicants to challenge remaining listed patents.
Which companies are challenging propoxyphene napsylate patents?
No material current patent-challenge activity is associated with propoxyphene napsylate. Generic manufacturers previously marketed propoxyphene products, but the relevant commercial competition ended after the FDA withdrawal.
The likely competitive set consisted of:
- Innovator products associated with Eli Lilly and related commercial entities.
- Generic manufacturers that marketed propoxyphene or propoxyphene combination products before withdrawal.
- Combination-product manufacturers offering propoxyphene with acetaminophen.
There is no current company-specific launch race comparable to an active small-molecule market. No significant settlement agreement, authorized-generic launch, or current Paragraph IV campaign is known to define the product’s commercial position.
What patent litigation affects propoxyphene napsylate?
Current patent litigation does not materially affect propoxyphene napsylate. Historical disputes, if any, would have involved expired product, formulation or generic-marketing rights rather than an active market protected by enforceable patents.
The key legal event was regulatory rather than patent-related: FDA’s 2010 withdrawal request. After withdrawal, litigation exposure shifted from ordinary generic-entry disputes toward product-liability and safety issues. Those issues do not create a viable basis for commercial relaunch.
What is the market size for propoxyphene napsylate?
The current U.S. market is effectively zero. The product has no active branded sales channel, no standard reimbursement position and no normal wholesale distribution.
| Market metric |
Current assessment |
| U.S. branded revenue |
Approximately zero |
| U.S. generic revenue |
Approximately zero |
| Active prescription demand |
Negligible |
| Hospital formulary presence |
Not commercially meaningful |
| Reimbursement opportunity |
None of practical significance |
| New patient acquisition |
Not applicable |
| Market share |
No active market share |
| Five-year growth outlook |
Flat at zero absent an extraordinary regulatory reversal |
Historical revenue cannot be used as a basis for a forward forecast. Before withdrawal, propoxyphene products had established prescription demand as opioid analgesics. That demand was structurally impaired by safety restrictions, declining prescribing and the eventual market withdrawal.
What is the projected market for propoxyphene napsylate?
The base-case forecast is no commercial revenue through the medium term in the United States and other major regulated markets where propoxyphene products were withdrawn or restricted.
Base-case forecast
| Period |
Projected commercial status |
| 2025-2026 |
No meaningful approved-product market |
| 2027-2029 |
No meaningful market expected |
| 2030 and later |
No market absent a major regulatory reversal |
A relaunch would require several events:
- A sponsor would need to establish a legally and commercially acceptable product.
- New clinical data would need to address cardiac electrophysiology and overdose risk.
- FDA would need to accept the benefit-risk profile despite the prior withdrawal.
- A manufacturing and distribution system would need to be re-established.
- Prescribers, payers and pharmacies would need to accept the product against safer opioid and non-opioid alternatives.
That sequence has a low probability because alternative analgesics are available and the original safety concern is intrinsic to propoxyphene exposure.
What manufacturing and intellectual-property barriers exist?
Manufacturing is technically feasible but commercially unattractive. Propoxyphene napsylate is a conventional small-molecule active ingredient rather than a biologic requiring complex cell-line or delivery-platform protection. The relevant manufacturing requirements would include controlled-substance handling, impurity control, analytical testing, stability data and compliance with current good manufacturing practices.
The main barriers are:
- Regulatory reapproval after withdrawal.
- Cardiac-safety characterization.
- Controlled-substance supply-chain requirements.
- Limited prescriber demand.
- Product-liability exposure.
- Competition from safer analgesic options.
- Absence of meaningful exclusivity to offset development cost.
The product does not present a biosimilar opportunity. Biosimilar rules apply to biological products, whereas propoxyphene napsylate is a small-molecule drug. Any future entrant would follow a small-molecule abbreviated or full application pathway, depending on the regulatory status and formulation.
How does propoxyphene napsylate compare with competing analgesics?
Propoxyphene napsylate is commercially disadvantaged against both opioid and non-opioid alternatives.
| Product category |
Commercial position versus propoxyphene napsylate |
| Acetaminophen |
Widely available, inexpensive and not subject to propoxyphene’s specific cardiac warning |
| NSAIDs |
Established alternatives, although they have their own renal, gastrointestinal and cardiovascular risks |
| Tramadol |
Alternative centrally acting analgesic with a current prescription market |
| Hydrocodone products |
Active opioid market with established prescribing and regulatory controls |
| Oxycodone products |
Active opioid market with higher analgesic potency |
| Buprenorphine |
Active products with pain and opioid-use-disorder applications |
| Non-opioid specialty analgesics |
Continued development and commercial investment |
Propoxyphene’s historical positioning as a lower-potency opioid does not provide a current competitive advantage. The market has moved toward alternative analgesics with stronger clinical adoption, more established regulatory frameworks or more favorable benefit-risk profiles.
What licensing deals involve propoxyphene napsylate?
No active licensing transaction is commercially significant. Historical licensing and distribution arrangements may have supported branded and generic marketing, but those arrangements have no current strategic value after withdrawal.
A new licensing deal would require more than rights to the chemical entity. It would need to address clinical redevelopment, regulatory liability, controlled-substance operations and potential product-liability claims. Those requirements reduce the likelihood of a conventional asset sale or regional licensing transaction.
Is there a biosimilar or generic launch risk?
There is no meaningful current generic-launch risk because the reference product is withdrawn and there is no active approved market to capture. A generic manufacturer could theoretically pursue a regulatory pathway, but approval would not guarantee commercial access. The sponsor would face the same safety and market-acceptance problems that led to withdrawal.
Generic-entry risk is therefore replaced by regulatory-relaunch risk. The principal question is not whether patents block entry. It is whether any sponsor could justify renewed marketing of the active ingredient.
Key Takeaways
- Propoxyphene napsylate was withdrawn from the U.S. market in 2010 because of cardiac electrophysiologic risk.
- No active clinical-development program or meaningful commercial market is evident.
- Historical composition, formulation and regulatory exclusivity have no current commercial value.
- No material Paragraph IV campaign, patent settlement or active litigation strategy defines the product.
- The product is a small molecule, so biosimilar competition is not relevant.
- Current U.S. revenue is effectively zero, and the base-case forecast remains zero through the medium term.
- Any relaunch would require extensive safety redevelopment and a new FDA benefit-risk determination.
- Safer and better-established analgesic alternatives make commercial redevelopment unlikely.
FAQs
Could propoxyphene napsylate return to the U.S. market?
A return would require a new sponsor and substantial clinical, cardiac-safety and regulatory work. The prior withdrawal makes a commercial return unlikely.
Is propoxyphene napsylate still available outside the United States?
Availability varies by jurisdiction, but major regulators took action against propoxyphene products. Local regulatory status should not be inferred from historical availability.
Can a generic company file an ANDA for propoxyphene napsylate?
A generic sponsor could evaluate an abbreviated application pathway, but approval and commercial launch would face substantial safety and market barriers. Patent expiry would not resolve those issues.
Does propoxyphene napsylate have an active Orange Book patent?
No current patent position has practical commercial significance. Historical patents associated with the product are expired or irrelevant to an active market.
What replaced propoxyphene napsylate in pain treatment?
Prescribers generally moved to non-opioid analgesics, NSAIDs, acetaminophen, tramadol and other opioid products, depending on the indication, patient risk and applicable prescribing controls.
References
- U.S. Food and Drug Administration. (2010, November 19). FDA recommends against the continued use of propoxyphene.
- U.S. Food and Drug Administration. (2011). Drug safety communication: FDA recommends against the continued use of propoxyphene.
- European Medicines Agency. (2009). European Medicines Agency recommends withdrawal of dextropropoxyphene-containing medicines.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. [Orange Book].
